Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection

被引:17
|
作者
Moscardó, F [1 ]
Sanz, GF [1 ]
de la Rubia, J [1 ]
Jiménez, C [1 ]
Saavedra, S [1 ]
Regadera, A [1 ]
Andreu, R [1 ]
García, I [1 ]
Plumé, G [1 ]
Martínez, J [1 ]
Martín, G [1 ]
Jarque, I [1 ]
Sanz, MA [1 ]
机构
[1] Hosp Univ La Fe, Dept Hematol, Bone Marrow Transplant Unit, Valencia 46009, Spain
关键词
CD34(+) selection; allogeneic hematopoietic stem cell transplantation; hepatic veno-occlusive disease;
D O I
10.1038/sj.bmt.1703025
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Veno-occlusive disease of the liver (VOD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT), To determine the incidence of, and the risk factors for the development of VOD, we performed a retrospective analysis of a series of 178 patients, who underwent allogeneic HSCT at our institution between 1990 and 1999, Busulfan and cyclophosphamide constituted the conditioning regimen most frequently administered. Bone marrow was the source of stem cells in 129 patients (73%), and peripheral blood (PBSC) in 49 patients (27%), Thirty-one patients of the PBSC group received CD34(+) positively selected grafts. Most patients were given cyclosporin A and methotrexate (MTX) as graft-versus-host disease (GVHD) prophylaxis. Overall, 30 patients (17%) developed VOD, In univariate analyses, the incidence of VOD was significantly higher in recipients of unmanipulated grafts (20% vs 0%; P=0.01), in patients with active malignant disease at transplantation (24% vs 9%; P = 0.03), in recipients of marrow from unrelated donors (33% vs 15%; P = 0.03), in patients grafted with bone marrow (21% vs 6%; P = 0.03), and in those receiving MTX as GVHD prophylaxis (21% vs 6%; P = 0.05), Under multivariate analysis, only CD34(+) positive selection (P = 0.0004) and the status of the disease at transplant (P = 0.03) were statistically significant variables for the development of VOD, We conclude that CD34(+) positively selected PBSC transplantation could result in a marked reduction in the incidence of VOD after allogeneic HSCT.
引用
收藏
页码:983 / 987
页数:5
相关论文
共 50 条
  • [41] Retrospective Application of Sinusoidal Obstruction Syndrome/Veno-occlusive Disease Diagnostic Criteria in a Pediatric Hematopoietic Stem Cell Transplant Cohort
    Dhir, Aditi
    Wadhwa, Aman
    Haines, Hilary
    Chewning, Joseph
    Murthy, Susmita
    Kim, Justin
    Beatty, Lisa
    Mixon, Emily
    Fowler, Karen B.
    Gage, Jarrod
    Meadows, Teresa
    Goldman, Frederick
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (02) : E343 - E348
  • [42] Early-onset hepatic veno-occlusive disease after liver transplantation: an institutional experience and analysis of a literature-based cohort
    Endo, Yutaka
    Shinoda, Masahiro
    Maehara, Junki
    Hibi, Taizo
    Hasegawa, Yasushi
    Obara, Hideaki
    Kitago, Minoru
    Ojima, Hidenori
    Tanabe, Minoru
    Kitagawa, Yuko
    SURGERY TODAY, 2024, 54 (07) : 670 - 682
  • [43] Ideal or actual body weight to calculate CD34+cell doses for allogeneic hematopoietic stem cell transplantation?
    Cilley, J
    Rihn, C
    Monreal, J
    Gordon, LI
    Singhal, S
    Tallman, M
    Williams, S
    Winter, J
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2004, 33 (02) : 161 - 164
  • [44] Use of CRRT-CVVH in a hemato-oncological ICU in patients treated with defibrotide for veno-occlusive disease in patients after allogeneic hematopoetic stem cell transplantation: single-center experience
    M Navratil
    Z Koristek
    F Folber
    Critical Care, 14 (Suppl 1):
  • [45] Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning
    Barba, P.
    Martino, R.
    Perez-Simon, J. A.
    Fernandez-Aviles, F.
    Pinana, J. L.
    Valcarcel, D.
    Campos-Varela, I.
    Lopez-Anglada, L.
    Rovira, M.
    Novelli, S.
    Lopez-Corral, L.
    Carreras, E.
    Sierra, J.
    BONE MARROW TRANSPLANTATION, 2012, 47 (10) : 1343 - 1349
  • [46] Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
    Jun Liu
    Jiang F. Zhong
    Xi Zhang
    Cheng Zhang
    Journal of Hematology & Oncology, 10
  • [47] Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
    Liu, Jun
    Zhong, Jiang F.
    Zhang, Xi
    Zhang, Cheng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 8
  • [48] Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation:: incidence, predictors and outcome
    Skert, C
    Patriarca, F
    Sperotto, A
    Cerno, M
    Filì, C
    Zaja, F
    Stocchi, R
    Geromin, A
    Damiani, D
    Fanin, R
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 258 - 261
  • [49] Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes
    Yakushijin, K.
    Atsuta, Y.
    Doki, N.
    Yokota, A.
    Kanamori, H.
    Miyamoto, T.
    Ohwada, C.
    Miyamura, K.
    Nawa, Y.
    Kurokawa, M.
    Mizuno, I.
    Mori, T.
    Onizuka, M.
    Taguchi, J.
    Ichinohe, T.
    Yabe, H.
    Morishima, Y.
    Kato, K.
    Suzuki, R.
    Fukuda, T.
    BONE MARROW TRANSPLANTATION, 2016, 51 (03) : 403 - 409
  • [50] Multiplex Proteomics in the Identification of Potential Biomarkers of Very Severe Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Hematopoietic Cell Transplant Patients Treated with Defibrotide
    Nampoothiri, Ram Vasudevan
    Avery, Lisa
    Pasic, Ivan
    Prassas, Ioannis
    Diamandis, Eleftherios
    Michelis, Fotios V.
    ACTA HAEMATOLOGICA, 2024, 147 (05) : 511 - 524